Kristen Morrow
Family · Vermillion, SDNPI 1245670801
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 17.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $820, more than ten times the $80 reported in 2021. Among family clinicians in SD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 152 payments — averaging $15.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$410
- Lilly USA, LLC$237
- Otsuka America Pharmaceutical, Inc.$236
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$214
- Pfizer$200
- Vanda Pharmaceuticals Inc.$190
- plus $912 from 20 others
What the payments were for
- Food & beverage$2,398100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 33 | $410 |
| Lilly USA, LLC | 19 | $237 |
| Otsuka America Pharmaceutical, Inc. | 14 | $236 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 17 | $214 |
| Pfizer | 11 | $200 |
| Vanda Pharmaceuticals Inc. | 10 | $190 |
| Boehringer Ingelheim | 9 | $167 |
| Supernus Pharmaceuticals, Inc. | 3 | $117 |
| Johnson & Johnson | 4 | $80 |
| Axsome Therapeutics, Inc. | 3 | $69 |
| Alkermes, Inc. | 3 | $66 |
| Amgen | 3 | $50 |
| Exact Sciences | 3 | $48 |
| E.r. Squibb & Sons, L.L.C. | 3 | $48 |
| Novo Nordisk | 3 | $44 |
| Astellas Pharma US Inc | 2 | $33 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
| Mylan Specialty L.p. | 1 | $24 |
| Corium, LLC | 2 | $22 |
| Medtronic | 1 | $20 |
| Abbott | 1 | $18 |
| Biomarin Pharmaceutical Inc. | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Novartis | 1 | $13 |
| Dexcom, Inc. | 1 | $12 |
How this compares
$2,398 in reported general payments places this provider in the 90th percentile of 588 family providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 12 | $11,655 |
| FarxigaDapagliflozin Propanediol | 13 | $7,789 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $4,529 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 11 | $1,224 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 13 | $1,145 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $723 |
| Potassium Chloride | 29 | $667 |
| Bupropion XlBupropion Hcl | 25 | $511 |
| Rosuvastatin Calcium | 40 | $455 |
| Bumetanide | 18 | $391 |
| Pantoprazole Sodium | 68 | $375 |
| Atorvastatin Calcium | 73 | $350 |
| Methylphenidate ErMethylphenidate Hcl | 13 | $336 |
| FenofibrateFenofibrate Nanocrystallized | 13 | $327 |
| Primidone | 15 | $324 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $44 | $11,65512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 588 family providers in South Dakota.
Other family in Vermillion
- Amanda AndersonVermillion$4K
- Brittany WangsnessSioux Falls$79K
- Stephanie PreisterSioux Falls$12K
- Claudia HouglandRapid City$9K
- Maria AzpeitiaDakota Dunes$8K
- Michelle VanhoveSioux Falls$7K
- Sandra EricksonHerreid$7K
- Melissa OwensRapid City$6K
- Heidi FurthSioux Falls$6K
- Tabitha AmmannSioux Falls$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.